Carolina discusses the controversial approval process of a drug that, despite showing no significant improvement in memory or function, was pushed through by the company after a failed efficacy analysis. The internal lobbying efforts and manipulation of study data raise questions about the integrity of drug approvals and the focus on amyloid as a treatment target. The conversation emphasizes the need for a critical reevaluation of what truly matters in Alzheimer's treatment.
